Phase II Trial of Hu14.18-IL2 (EMD 273063) in Subjects With Advanced Melanoma
Phase of Trial: Phase II
Latest Information Update: 24 Sep 2015
At a glance
- Drugs Monoclonal antibody ch14 18 interleukin-2 fusion protein (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 14 Jan 2009 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
- 18 Oct 2007 Status changed from recruiting to suspended.